|
Virtual Mentor. July 2003, Volume 5, Number 7. Suggested Reading and Resources Resources on Medicine and IndustryRelated Opinions from the AMA’sCode of Medical
Ethics American Medical Association. Opinion 8.06 Prescribing and dispensing drugs and devices. Code of Medical Ethics and Current Opinions, 2002-2003 edition. Chicago: American Medical Association; 2002:91-92. Accessed June 30, 2003. American Medical Association. Opinion
8.061 Gifts to physicians from industry. Code of Medical Ethics and Current
Opinions, 2002-2003 edition. Chicago: American Medical Association; 2002:92-102.
Accessed June 30, 2003. American Medical Association. Opinion 9.011 Continuing Medical Education. Code of Medical Ethics and Current Opinions, 2002-2003 edition. Chicago: American Medical Association; 2002:121-123. Accessed June 30, 2003. American Medical Association. E-11.02 Clarification of Opinion 8.061. Code of Medical Ethics and Current Opinions. Accessed June 30, 2003. Resources Accreditation Council for Continuing Medical
Education. Income and expense for all ACCME accredited providers--2001. Available
at: www.accme.org/incoming/125_2001_Annual_Report_Data.pdf. Accessed May 15,
2003. Accreditation Council for Continuing Medical
Education. Standards for commercial support of continuing medical education.
Available at: www.accme.org/pdfs/disclosure_pol.pdf. Accessed May 15, 2003. Accreditation Council for Graduate Medical Education.
Principles to guide the relationship between graduate medical education and
industry. Available at: www.acgme.org/New/GMEGuide.pdf. Accessed March 24, 2003. Adams C. Student doctors protest largess of drug
makers. Wall Street Journal. June 24, 2002;B1. ALLHAT - So What? J Inform Pharmacother 2003;12:1. American College of Physicians. Physicians and the pharmaceutical industry. Ann Intern Med. 1990; 112:624-626. American Medical Association
Council on Ethical and Judicial Affairs. Gifts to physicians from industry.
JAMA. 1991;265:501. American Medical Student Association. AMSA PharmFree
Campaign. Available at: www.amsa.org/prof/pharmfree.cfm. Accessed May 31, 2003. American Medical Student Association. Revitalizing
professionalism. Available at: www.amsa.org/prof/. Accessed May 31, 2003. Barzansky B, Etzel SI. Educational programs in
US medical schools, 2000-2001. JAMA. 2001;286:1049-1055. Bekelman JE, Li Y, Gross CP. Scope and impact
of financial conflicts of interest in biomedical research. JAMA. 2003;289:454-65. Best Pharmaceuticals for Children Act (21 USC 505) (BPCA).1997. BIO. Biotechnology industry
statistics. Available at: http://www.bio.org/er/statistics.asp.
Accessed: May 27, 2003. Blood Pressure Lowering Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000;356:1955. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Eng J Med. 2000;342:1539-44. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8:13-20. Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius.1986;6:66-69. Boyd EA, Bero LA. Assessing faculty financial
relationships with industry: a case study. JAMA. 2000;284:2209-14. Brody H. A matter of influence. Health Affairs.
March/April 2002;21:232-234. Cho MK, Bero LA. The quality of drug studies
published in symposium proceedings. Ann Intern Med. 1996;124:485-89. Chobanian AV, Bakris GL, Black HR, et al and
the National High Blood Pressure Education Program Coordinating Committee. The
seventh report of the joint national committee on prevention, detection, evaluation,
and treatment of high blood pressure: The JNC report. JAMA. 2003;289:2560-2572. Chren M-M, Landefeld CS, Murray TH. Doctors, drug companies, and gifts. JAMA. 1989; 262:3448-51. CONSORT. Available at: http://www.consort-statement.org/. Accessed June 27, 2003. Council on Ethical and Judicial Affairs. E-Addendum
II: Council on Ethical and Judicial Affairs clarification of gifts to physicians
from industry (E-8.061). June 2002. Available at: www.ama-assn.org/ama/pub/article/4001-4388.html.
Accessed May 31, 2003. Council on Scientific Affairs and Council on Ethical and Judicial Affairs, American Medical Association. Conflicts of interest in medical center/industry research relationships. JAMA. 1990;263:2790. Coyle SL. Physician-industry relations. Part
1; Individual physicians. Ann of Intern Med. 2002;136:396-402. Coyle SL. Physician-industry relations. Part
2: Organizational issues. Ann of Intern Med. 2002;136:403-406. DuBois JM, Burkemper J. Ethics education in US
medical schools: A study of syllabi. Acad Med. 2002;77:432-437. Ethics Manual: Fourth Edition. Ann of Intern
Med. 1998;128:576-594. Ferguson RP, Rhim E, Belizaire W, et al. Encounters
with pharmaceutical sales representatives among practicing internists. Am
J Med. August 1999;107:149-152. Frankel M. Perception, reality, and the political
context of conflict of interest in university-industry relationships. Acad
Med. 1996;71:1297-1304. Frohlich ED. Treating hypertension. What are
we to believe? N Engl J Med. 2003;348:639-641. Gibbons RV, Landry FJ, Blouch DL, et al. A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med. 1998; 13:151-154. Goldhammer A. Current issues in clinical research
and the development of new pharmaceuticals. Accountability in Research. 2000;8:283-91. Goodman B. No free lunch. Available at: www.nofreelunch.org. Accessed May 31, 2003. HHS Office of Inspector General. Compliance
program guidance for pharmaceutical manufacturers. April 2003. Accessed
June 25, 2003. HHS Office of Inspector General. Medicare and state health care programs: Fraud and abuse; OIG anti-kickback provisions. 56 Federal Registrar 3592. HHS Office of Inspector General. OIG compliance program guidance for pharmaceutical manufacturers. 68 Federal Registrar 23731. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. 2000;160:2281-6. IMS Health Incorporated. Total
US promotional spending by type. March 2003. Accessed May 28, 2003. Jung P. No free lunch. Health Affairs.
April 2002;21:226-231. Kelcher S, Brownoff R, Meadows LM. Structured
approach to pharmaceutical representatives. Canadian Family Physician.
1998;44:1053-1060. Kopelman L. Children as research subjects: a
dilemma. Journal of Medicine and Philosophy. 2000;25:745-64. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical
industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70. Makoff D. Science agencies get most of what they
want, finally. Science 2003; 299:1160-61. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky
AS. Effect of restricting contact between pharmaceutical company representatives
and internal medicine residents on posttraining attitudes and behavior. JAMA.
2001;286:1994-1999. Monaghan MS, Galt KA, Turner PD, et al. Student
understanding of the relationship between the health professions and the pharmaceutical
industry. Teaching and Learning in Medicine. 2003;15:14-20. Moser M. Results of ALLHAT. Is this the final answer regarding initial antihypertensive drug therapy? Arch Intern Med. 2003;163:1269-1273. Moses H, Martin JB. Academic relationships with
industry: a new model for biomedical research. JAMA. 2001;285:933-35. NIH. Questions and answers
about the NIH. Available at: http://www.nih.gov/about/Faqs.htm#NIH.
Accessed: May 27, 2003. Objectivity in Research, 60 Federal Register 35810 (1995) (codified at 45 CFR, 94). Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing behavior: there’s no such thing as free lunch. Chest.1992; 102:270-273. Orphan Drug Act (ODA) (Public Law 97-414). 1983. Pahor M and colleagues. Health outcomes associated with calcium channel antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet. 2000;356:1949. Pearson S-A, Rolfe I, Smith T. Factors influencing prescribing: an intern's perspective. Medical Education. August 2002;36:781-787. Pharmaceutical Research and Manufacturers of America. PhRMA:
Industry Profile 2003 (Chapter 2). Accessed June 30, 2003. Pharmaceutical Research and Manufacturers of America. The PhRMA code on interactions with healthcare professionals. Available at: http://www.phrma.org/publications/policy//2002-04-19.391.pdf. Accessed June 27, 2003. PHRMA. Intellectual property.
Available at: http://www.phrma.org/issues/intprop/.
Accessed: May 27, 2003. PHRMA. Research and development.
Available at: http://www.phrma.org/issues/researchdev/.
Accessed: May 27, 2003. Pritchard MS. Conflicts of interest: conceptual
and normative issues. Acad Med.1996;71:1305-13. Pritchett HS. Introduction. In: Flexner A, ed. Medical Education in the United States and Canada: A Report to the Carnegie Foundation for the Advancement of Teaching. Reprint. New York: Arno Press Inc; 1972:xiii-xiv. Razack S, Arbour L, Hutcheon R. Proposed model
for interaction between residents and residency training programs, and pharmaceutical
industry. Annals of the Royal College of Physicians and Surgeons of Canada.
March 1999;32:93-96. Resnik D. Developing drugs for the developing
world: an economic, legal, moral and political dilemma. Developing World
Bioethics. 2001;1:11-32. Resnik D. Setting biomedical research priorities:
justice, science, and public participation. Kennedy Institute of Ethics Journal. 2001;11:181-204. Romano M. Student rally. Modern Healthcare.
May 13 2002;32:24-25. Rothman DJ. Medical professionalism: focusing
on the real issues. New Engl J Med. 2000;342:1284-1286. Santana S. AAMC executive council sets guidelines
on industry marketing to residents. Association of American Medical Colleges.
Available at: www.aamc.org/newsroom/reporter/april03/executivecouncil.htm. Accessed
May 27, 2003. Smith R. Beyond conflict of interest. BMJ. 1998;137:291-2. Tauer C. Ethical dilemmas on research on children. Accountability in Research. 2002;9:127-42. The ALLHAT Officers and Coordinators for the
ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive
patients randomized to angtiotensin-converting enzyme inhibitor or calcium channel
blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent
heart attack (ALLHAT). JAMA. 2002;288:2981-2997. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-46. Thompson DF. Understanding financial conflict of interest. N Engl J Med. 1993;329:573-576. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. B J Gen Pract. 1994; 44:220-223. US Food and Drug Administration. FDA: Final guidance
on industry-supported scientific and educational activities. 62 FR 64074. Wazana A. Is a gift ever just a gift? A critical
review of the interaction between physicians and the pharmaceutical industry.
JAMA. 2000;283:373-380. Wazana A, Primeau F. Ethical considerations in the relationship between physicians and the pharmaceutical industry. Psychiatric Clinics of North America. 2002;25:647-663. Wilkes MS, Hoffman JR. An innovative approach
to educating medical students about pharmaceutical promotion. Acad Med.
2001;76:1271-1277. Wing LMH, Reid CM, Ryan P, et al for the Second
Australian National Blood Pressure Study Group. A comparison of outcomes with
angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the
elderly. N Engl J Med. 2003;348:583-592. Wolfe SM. The destruction of medicine by market
forces: teaching acquiescence or resistance and change? Acad Med. 2002;77:5-7. Wolfsthal SD, Beasely BW, Kopelman R, et al.
Benchmarks of support in internal medicine residency training programs. Acad
Med. 2002;77:50-56. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical representatives. JAMA. 1995;273:1296-1298. Legal and Regulatory Resources 46 CFR §164.508(a)(3)(ii). US v Perlstein, 632 F2d 661 (Mich Ct App
1980).
The viewpoints expressed on this site are those of the authors and do not necessarily reflect the views and policies of the AMA.
© 2003 American Medical Association. All Rights Reserved. |